<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.moneycontrol.com/news/business/glenmark-gets-usfda-nod-for-generic-acne-treatment-gel-2-4626381.html"/>
    <meta property="og:site_name" content="Moneycontrol"/>
    <meta property="article:published_time" content="2019-11-11T00:00:00+00:00"/>
    <meta property="og:title" content="Glenmark gets USFDA nod for generic acne treatment gel"/>
    <meta property="og:description" content="The approval granted to Glenmark Pharmaceuticals Inc by the US Food and Drug Administration is for Adapalene and Benzoyl Peroxide Gel, 0.1 per cent/2.5 per cent, which is the the generic version of Epiduo gel, 0.1 per cent/2.5 per cent of of Galderma Laboratories LP, the company said in a statement."/>
  </head>
  <body>
    <article>
      <h1>Glenmark gets USFDA nod for generic acne treatment gel</h1>
      <h2>The approval granted to Glenmark Pharmaceuticals Inc by the US Food and Drug Administration is for Adapalene and Benzoyl Peroxide Gel, 0.1 per cent/2.5 per cent, which is the the generic version of Epiduo gel, 0.1 per cent/2.5 per cent of of Galderma Laboratories LP, the company said in a statement.</h2>
      <address><time datetime="2019-11-11T00:00:00+00:00">11 Nov 2019</time> by <a rel="author">PTI</a></address>
      <p>Glenmark Pharmaceuticals on Monday said it has received final approval from the US health regulator for generic Adapalene and Benzoyl Peroxide gel used in treatment of acute acne.</p>
      <p>The approval granted to Glenmark Pharmaceuticals Inc by the US Food and Drug Administration is for Adapalene and Benzoyl Peroxide Gel, 0.1 per cent/2.5 per cent, which is the the generic version of Epiduo gel, 0.1 per cent/2.5 per cent of of Galderma Laboratories LP, the company said in a statement.</p>
      <p>Citing IQVIA sales data for the 12 month period ending September 2019, Glenmark said Epiduo Gel, 0.1 per cent/2.5 per cent had achieved annual sales of approximately USD 33.7 million.</p>
      <p><a href="https://www.moneycontrol.com/news/business/javascript:;">Close<br/></a>The company's current portfolio consists of 163 products authorised for distribution in the US and 45 abbreviated new drug applications (ANDAs) pending approval with the USFDA.<a href="https://www.moneycontrol.com/promos/pro.php">Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights &amp; analysis For more information, check out the Moneycontrol website or mobile app.</a></p>
    </article>
  </body>
</html>